{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056902","form_type":"8-K","ticker":null,"cik":"0001564824","company_name":"Allakos Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.991945+00:00","generated_at":"2026-06-02T05:53:28.409081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allakos Q1 net loss $71.1M ($0.81/sh); cash burn $31.5M; impairment $27.3M","bullets":["Net loss $71.1M vs $42.4M YoY; diluted EPS $(0.81) vs $(0.49); non-cash impairment charge $27.3M from lirentelimab halt.","Cash, equivalents, investments $139.3M at March 31; net decrease $31.5M in Q1; runway extended into mid-2026.","Restructuring costs for lirentelimab closeout ~$30M total; $12M paid in Q1, remaining ~$18M expected Q2-Q3 2024.","Completed Phase 1 dosing of AK006 (IV and SC) in healthy volunteers; initiated Phase 1 trial in chronic spontaneous urticaria.","Upcoming milestones: Phase 1 healthy volunteer data Q2/Q3 2024; CSU topline data year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056902","json":"https://secwatch.observer/filing/0000950170-24-056902.json","markdown":"https://secwatch.observer/filing/0000950170-24-056902.md","text":"https://secwatch.observer/filing/0000950170-24-056902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/0000950170-24-056902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/allk-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:53:28.409081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e5f8e84425d33f5fbc9c0e3bd41bf06dba1d581","claim":"Allakos Inc. updated its the first quarter ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"On May 9, 2024, Allakos Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1564824/000095017024056902/0000950170-24-056902-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}